AMGN - Amgen

-

$undefined

N/A

(N/A)

Amgen NASDAQ:AMGN Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Location: 1 Amgen Center Dr, California, 91320-1799, US | Website: www.amgen.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

225.1B

Cash

9.301B

Avg Qtr Burn

N/A

Short % of Float

1.83%

Insider Ownership

0.25%

Institutional Own.

81.64%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TAVNEOS (Avacopan) (C5aR) Details
ANCA-Associated Vasculitis, Autoimmune disease

Approved

Quarterly sales

BLINCYTO® (blinatumomab) Details
B-cell acute lymphoblastic leukemia

Approved

Quarterly sales

KRYSTEXXA Details
Chronic refractory gout

Approved

Quarterly sales

Approved

Quarterly sales

BLINCYTO® (blinatumomab) Details
B-cell acute lymphoblastic leukemia

Approved

Quarterly sales

IMDELLTRA (Tarlatamab) (AMG 757) Details
Lung cancer, Cancer, Small cell lung cancer

Approved

Quarterly sales

TEPEZZA Details
Thyroid Eye Disease , Eye disease

Approved

Quarterly sales

BLA

Submission

Olpasiran (AMG 890) Details
Atherosclerotic cardiovascular disease

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Data readout

TEZSPIRE Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Nplate® Details
Chemo-induced thrombocytopenia

Phase 3

Data readout

Rocatinlimab Details
Atopic dermatitis

Phase 3

Data readout

LUMAKRAS/LUMYKRAS (sotorasib) Details
Non-small cell lung carcinoma

Phase 3

Data readout

UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details
Neuromuscular disease, Myasthenia gravis

Phase 3

Update

TAVNEOS (Avacopan) (C5aR) Details
Skin disease/disorder, Hidradenitis suppurativa

Phase 3

Update

Phase 3

Initiation

Fipaxalparant (AMG 670) (HZN-825) Details
Idiopathic pulmonary fibrosis

Phase 2b

Data readout

Phase 2

Data readout

Phase 2

Data readout

Dazodalibep (HZN-4920) Details
Kidney disease, Lupus nephritis, Autoimmune disease

Phase 2

Data readout

Phase 2

Data readout

UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details
Kidney transplantation, Kidney disease

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

TAVNEOS (Avacopan) (C5aR) Details
Kidney disease, C3 Glomerulopathy

Phase 2

Update

Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details
Arthritis, Congenital adrenal hyperplasia, Genetic disorder, Autoimmune disease, Rheumatoid arthritis

Phase 2

Update

Tezspire Details
Chronic obstructive pulmonary disease

Phase 2a

Update

Phase 1b

Data readout

IMDELLTRA (Tarlatamab) (AMG 757) + PD-L1 inhibitor Details
Small cell lung cancer, Lung cancer, Cancer

Phase 1b

Update

HZN-457 Details
Chronic refractory gout

Phase 1

Data readout

AMG 193 Details
Cancer, Solid tumor/s

Phase 1

Data readout

Xaluritamig Details
Cancer, Castration-resistant prostate cancer

Phase 1

Data readout

Phase 1

Update